Holen Sie sich die Stockscreener-App
14.17
0.28%
-0.04
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Leadership Reveals Growth Strategy at Elite Healthcare Investment Forums - StockTitan
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Consensus Target Price from Brokerages - MarketBeat
Syndax Looks Tantalizing, But Looks Can Be Deceptive - Seeking Alpha
Syndax Pharmaceuticals (FRA:1T3) Net-Net Working Capital : €3.67 (As of Sep. 2024) - GuruFocus.com
How the (SNDX) price action is used to our Advantage - Stock Traders Daily
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (FRA:1T3) Price-to-Operating-Cash-Fl - GuruFocus.com
Syndax Pharmaceuticals (FRA:1T3) ROE % Adjusted to Book Val - GuruFocus.com
Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes - Marketscreener.com
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - Lelezard
FDA Approves Niktimvo: Breakthrough Treatment for Chronic GVHD Shows 75% Response Rate - StockTitan
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs - Investing.com Nigeria
Syndax Pharmaceuticals (FRA:1T3) Cash From Discontinued Inv - GuruFocus.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $12.38 amid market challenges - Investing.com Nigeria
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowHere's Why - MarketBeat
Syndax Achieves Dual FDA Approvals for Breakthrough Cancer & GVHD Treatments in Major Growth Milestone - StockTitan
Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables : €4.23 Mil (As of Sep. 2024) - GuruFocus.com
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain - Yahoo Finance
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at Scotiabank - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - The Eastern Progress Online
Where are the Opportunities in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Jefferies maintains Buy rating on Syndax stock with $43 target By Investing.com - Investing.com Nigeria
Jefferies maintains Buy rating on Syndax stock with $43 target - Investing.com
Syndax Pharmaceuticals Awards 123,100 Stock Options to New Hires in Growth Initiative - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1%What's Next? - MarketBeat
Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
SNDX stock touches 52-week low at $12.75 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year LowWhat's Next? - MarketBeat
Syndax Pharmaceuticals, Inc. Announces Cessation of Catherine Madigan as Chief Medical Officer - Marketscreener.com
Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6%Should You Sell? - MarketBeat
Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals CMO position eliminated By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CMO position eliminated - Investing.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - cnhinews.com
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):